Document 3080 DOCN M94A3080 TI Immune activation markers and CD4 cells counts in HIV clinical stages. Predictors of advanced disease? DT 9412 AU Portilla J; Sanchez J; Boix V; Munoz C; Sen ML; Reus S; Perez-Mateo M; Hospital General de Alicante, Spain. SO Int Conf AIDS. 1994 Aug 7-12;10(1):158 (abstract no. PB0058). Unique Identifier : AIDSLINE ICA10/94369495 AB OBJECTIVE: To evaluate the relationship among serum neopterin, beta 2 microglobulin, IgG, IgA, IgM, clinical stage and CD4 lymphocyte counts. METHODS: In 108 HIV patients (IVDU 80%), 89 men and 19 women, we determined CD4 cells by flow cytometry; beta 2 microglobulin, IgG, IgA e IgM by immunonefelometry and serum neopterin by RIA. The patients were classificated according to the CDC staging system (1987): stage A (II, III), stage B (IVA, IVC2), stage C (case definition for AIDS, CDC 1987). Statistical analysis: analisis of variance, Student's t-test and Pearson's correlation test. TABULAR DATA, SEE ABSTRACT VOLUME. There was no correlation between the immune markers and the CD4 counts. CONCLUSIONS: 1) IgA levels are increased in advanced HIV disease. 2) IgA is the only immunoglobulin with prognostic value. 3) Elevations of IgA and serum neopterin and run down of CD4 cell counts are independents markers of AIDS. 4)Like others, this study shows that beta 2 microglobulin is not a good prognostic marker when HIV patients are preferently IVDU. DE beta 2-Microglobulin/METABOLISM Adult Biopterin/ANALOGS & DERIVATIVES/BLOOD Human HIV Infections/CLASSIFICATION/*DIAGNOSIS/IMMUNOLOGY Immunoglobulins/BLOOD *Leukocyte Count Lymphocyte Transformation/*IMMUNOLOGY Prognosis Substance Abuse, Intravenous/IMMUNOLOGY T4 Lymphocytes/*IMMUNOLOGY MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).